Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUSA-081 for Dysfunctional Central Venous Access Devices
NCT03992443Phase 3Withdrawn
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Metabolic Enzymes, Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of CUSA-081 in central venous catheter occlusion, sponsored by Chiesi Farmaceutici S.p.A.. Planned start Feb 2022; status: withdrawn.
02
Drugs
CUSA-081
03
Conditions
central venous catheter occlusion
Beyond the preview
Go deeper on NCT03992443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992443.